S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
NYSE:OGN

Organon & Co. (OGN) Stock Price, News & Analysis

$17.56
+0.15 (+0.86%)
(As of 03/1/2024 ET)
Today's Range
$17.25
$17.60
50-Day Range
$13.78
$18.71
52-Week Range
$10.84
$24.99
Volume
1.55 million shs
Average Volume
3.31 million shs
Market Capitalization
$4.49 billion
P/E Ratio
4.39
Dividend Yield
6.38%
Price Target
$23.67

Organon & Co. MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
34.8% Upside
$23.67 Price Target
Short Interest
Bearish
5.22% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.37
Upright™ Environmental Score
News Sentiment
1.11mentions of Organon & Co. in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$49,939 Bought Last Quarter
Proj. Earnings Growth
2.94%
From $4.08 to $4.20 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.98 out of 5 stars

Medical Sector

10th out of 957 stocks

Pharmaceutical Preparations Industry

4th out of 440 stocks


OGN stock logo

About Organon & Co. Stock (NYSE:OGN)

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

OGN Stock Price History

OGN Stock News Headlines

Organon & Co. (NYSE:OGN) Insider Buys $49,939.20 in Stock
Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
Organon Stock Is Still Worth A Look
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Organon & Co. (NYSE:OGN) Q4 2023 Earnings Call Transcript
Organon Stock (NYSE:OGN), Guidance and Forecast
Looking Into Organon's Recent Short Interest
Organon & Co (OGN) Fell on Missed Consensus
Why Organon & Co. Stock Popped Today
See More Headlines
Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Ex-Dividend for 12/14 Dividend
11/10/2023
Dividend Payable
12/14/2023
Ex-Dividend for 3/14 Dividend
2/23/2024
Today
3/01/2024
Dividend Payable
3/14/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
10,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.67
High Stock Price Target
$33.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+34.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$1.02 billion
Pretax Margin
10.75%

Debt

Sales & Book Value

Annual Sales
$6.26 billion
Cash Flow
$4.95 per share
Book Value
($0.27) per share

Miscellaneous

Free Float
252,647,000
Market Cap
$4.49 billion
Optionable
Not Optionable
Beta
0.79
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Kevin Ali (Age 64)
    CEO & Director
    Comp: $3.96M
  • Mr. Matthew M. Walsh (Age 57)
    Executive VP & CFO
    Comp: $1.84M
  • Ms. Susanne Gabriele Fiedler (Age 56)
    Executive VP & Chief Commercial Officer
    Comp: $1.44M
  • Mr. Joseph T. Morrissey Jr. (Age 59)
    Executive VP and Head of Manufacturing & Supply
    Comp: $1.54M
  • Ms. Rachel A. Stahler (Age 48)
    Executive VP & Chief Information Officer
  • Ms. Jennifer Halchak
    Vice President of Investor Relations
  • Mr. Kirke Weaver (Age 51)
    Executive VP, General Counsel & Corporate Secretary
  • Mr. Aaron Falcione (Age 53)
    Executive VP & Chief Human Resources Officer
  • Mr. Vittorio Nisita (Age 56)
    Executive VP & Head of Global Business Services
  • Ms. Meghan Rivera
    US Managing Director














OGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Organon & Co. stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" OGN shares.
View OGN analyst ratings
or view top-rated stocks.

What is Organon & Co.'s stock price target for 2024?

5 Wall Street research analysts have issued 12-month target prices for Organon & Co.'s stock. Their OGN share price targets range from $18.00 to $33.00. On average, they predict the company's share price to reach $23.67 in the next twelve months. This suggests a possible upside of 34.8% from the stock's current price.
View analysts price targets for OGN
or view top-rated stocks among Wall Street analysts.

How have OGN shares performed in 2024?

Organon & Co.'s stock was trading at $14.42 at the beginning of 2024. Since then, OGN stock has increased by 21.8% and is now trading at $17.56.
View the best growth stocks for 2024 here
.

Are investors shorting Organon & Co.?

Organon & Co. saw a drop in short interest in January. As of January 31st, there was short interest totaling 12,330,000 shares, a drop of 10.7% from the January 15th total of 13,810,000 shares. Based on an average daily trading volume, of 4,070,000 shares, the short-interest ratio is presently 3.0 days. Approximately 4.8% of the company's stock are sold short.
View Organon & Co.'s Short Interest
.

When is Organon & Co.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our OGN earnings forecast
.

How were Organon & Co.'s earnings last quarter?

Organon & Co. (NYSE:OGN) posted its quarterly earnings data on Tuesday, August, 8th. The company reported $1.31 EPS for the quarter, beating the consensus estimate of $0.97 by $0.34. The business had revenue of $1.61 billion for the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a negative trailing twelve-month return on equity of 212.00% and a net margin of 16.33%. The firm's quarterly revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.25 EPS.
Read the conference call transcript
.

How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?

Organon & Co. declared a quarterly dividend on Thursday, February 15th. Stockholders of record on Monday, February 26th will be paid a dividend of $0.28 per share on Thursday, March 14th. This represents a $1.12 dividend on an annualized basis and a yield of 6.38%. The ex-dividend date of this dividend is Friday, February 23rd.
Read our dividend analysis for OGN
.

Is Organon & Co. a good dividend stock?

Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 6.28%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 28.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 26.67% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for OGN.

What guidance has Organon & Co. issued on next quarter's earnings?

Organon & Co. issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $6.2 billion-$6.5 billion, compared to the consensus revenue estimate of $6.4 billion.

Who are Organon & Co.'s major shareholders?

Organon & Co.'s stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.97%), Massachusetts Financial Services Co. MA (3.99%), Sound Shore Management Inc. CT (1.83%), LSV Asset Management (1.31%), Point72 Asset Management L.P. (1.25%) and Nordea Investment Management AB (1.22%). Insiders that own company stock include Kirke Weaver and Ma Fatima Francisco.
View institutional ownership trends
.

How do I buy shares of Organon & Co.?

Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:OGN) was last updated on 3/1/2024 by MarketBeat.com Staff